Zogenix stock soars after epilepsy test success

(Reuters) - Zogenix Inc's experimental treatment for a rare form of epilepsy met the main goal in a late-stage study, the company said on Friday, putting it on track to request regulatory approval next year and more than tripling the value of its shares.